Бикалутамид Тева 150 мг
Country: Iżrael
Lingwa: Russu
Sors: Ministry of Health
Xi dokumenti għal dan il-prodott mhumiex disponibbli bħalissa, tista 'tibgħat talba lis-servizz tal-konsumatur tagħna u aħna ninnotifikawkom malli nkunu nistgħu niksbuhom.
Ibgħat talba.
Ibgħat talba.
Ingredjent attiv:
BICALUTAMIDE 150 MG
Disponibbli minn:
TEVA PHARMACEUTICAL INDUST.LTD
Kodiċi ATC:
L02BB03
Għamla farmaċewtika:
TABLETS
Rotta amministrattiva:
PER OS
Manifatturat minn:
TEVA PHARMACEUTICAL INDUSTRIES LTD
Grupp terapewtiku:
BICALUTAMIDE
Indikazzjonijiet terapewtiċi:
In patients with locally advanced prostate cancer (T3-T4 any N M0 T1-T2 N+ M0) Bicalutamide is indicated as immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy. The management of patients with locally advanced non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable.
Data ta 'l-awtorizzazzjoni:
2009-05-01
